<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32304669</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-0024</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Molecular therapy : the journal of the American Society of Gene Therapy</Title><ISOAbbreviation>Mol Ther</ISOAbbreviation></Journal><ArticleTitle>Enterovirus A71 Oncolysis of Malignant Gliomas.</ArticleTitle><Pagination><StartPage>1533</StartPage><EndPage>1546</EndPage><MedlinePgn>1533-1546</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymthe.2020.04.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1525-0016(20)30186-6</ELocationID><Abstract><AbstractText>Malignant gliomas, the most lethal type of primary brain tumor, continue to be a major therapeutic challenge. Here, we found that enterovirus A71 (EV-A71) can be developed as a novel oncolytic agent against malignant gliomas. EV-A71 preferentially infected and killed malignant glioma cells relative to normal glial cells. The virus receptor human scavenger receptor class B, member 2 (SCARB2), and phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)-mediated cell death were involved in EV-A71-induced oncolysis. In mice with implanted subcutaneous gliomas, intraneoplastic inoculation of EV-A71 caused significant tumor growth inhibition. Furthermore, in mice bearing intracranial orthotopic gliomas, intraneoplastic inoculation of EV-A71 substantially prolonged survival. By insertion of brain-specific microRNA-124 (miR124) response elements into the viral genome, we improved the tumor specificity of EV-A71 oncolytic therapy by reducing its neurotoxicity while maintaining its replication potential and oncolytic capacity in gliomas. Our study reveals that EV-A71 is a potent oncolytic agent against malignant gliomas and may have a role in treating this tumor in the clinical setting.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hanzhong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China; Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuhan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China; University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Mi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xian-En</ForeName><Initials>XE</Initials><AffiliationInfo><Affiliation>National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Zongqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: czq@wh.iov.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther</MedlineTA><NlmUniqueID>100890581</NlmUniqueID><ISSNLinking>1525-0016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051907">Lysosomal Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051116">Receptors, Scavenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C074299">SCARB2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017930" MajorTopicYN="N">Genes, Reporter</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051907" MajorTopicYN="N">Lysosomal Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="N">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051116" MajorTopicYN="N">Receptors, Scavenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">malignant gliomas</Keyword><Keyword MajorTopicYN="N">miR124</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32304669</ArticleId><ArticleId IdType="pmc">PMC7264442</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.005</ArticleId><ArticleId IdType="pii">S1525-0016(20)30186-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Osuka S., Van Meir E.G. Overcoming therapeutic resistance in glioblastoma: the way forward. J.&#xa0;Clin. Invest. 2017;127:415&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5272196</ArticleId><ArticleId IdType="pubmed">28145904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen P.Y., Kesari S. Malignant gliomas in adults. N.&#xa0;Engl. J. Med. 2008;359:492&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669428</ArticleId></ArticleIdList></Reference><Reference><Citation>Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842&#x2013;1850.</Citation><ArticleIdList><ArticleId IdType="pubmed">24193082</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012;30:658&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888062</ArticleId><ArticleId IdType="pubmed">22781695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 2007;15:651&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">17299401</ArticleId></ArticleIdList></Reference><Reference><Citation>Desjardins A., Gromeier M., Herndon J.E., 2nd, Beaubier N., Bolognesi D.P., Friedman A.H., Friedman H.S., McSherry F., Muscat A.M., Nair S. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N.&#xa0;Engl. J. Med. 2018;379:150&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065102</ArticleId><ArticleId IdType="pubmed">29943666</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsyth P.A., Abate-Daga D. Oncolytic Virotherapy for Malignant Gliomas. J.&#xa0;Clin. Oncol. 2018;36:1440&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pubmed">29437534</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenz E.J., Howe C.L. Picornaviruses and cell death. Trends Microbiol. 2006;14:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337385</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans D.J. Reverse genetics of picornaviruses. Adv. Virus Res. 1999;53:209&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">10582100</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zheng Z., Shu B., Liu X., Zhang Z., Liu Y., Bai B., Hu Q., Mao P., Wang H. Human astrocytic cells support persistent coxsackievirus B3 infection. J.&#xa0;Virol. 2013;87:12407&#x2013;12421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807905</ArticleId><ArticleId IdType="pubmed">24027313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., Koike S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med. 2009;15:798&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Iizuka S., Yamashita T., Minagawa H., Mizuta K., Okamoto M., Nishimura H., Sanjoh K., Katsushima N., Itagaki T. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J.&#xa0;Virol. 2012;86:5686&#x2013;5696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmer J.C., Salvesen G.S. Caspase substrates. Cell Death Differ. 2007;14:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082814</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288:1053&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">10807576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly E.J., Hadac E.M., Greiner S., Russell S.J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 2008;14:1278&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">18953352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Wang F., Kong L.Y., Xu S., Doucette T., Ferguson S.D., Yang Y., McEnery K., Jethwa K., Gjyshi O. miR-124 inhibits STAT3 signaling to enhance T&#xa0;cell-mediated immune clearance of glioma. Cancer Res. 2013;73:3913&#x2013;3926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3780786</ArticleId><ArticleId IdType="pubmed">23636127</ArticleId></ArticleIdList></Reference><Reference><Citation>He F., Yao H., Wang J., Xiao Z., Xin L., Liu Z., Ma X., Sun J., Jin Q., Liu Z. Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice. J.&#xa0;Virol. 2015;89:908&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300646</ArticleId><ArticleId IdType="pubmed">25339771</ArticleId></ArticleIdList></Reference><Reference><Citation>Brostoff T., Pesavento P.A., Barker C.M., Kenney J.L., Dietrich E.A., Duggal N.K., Bosco-Lauth A.M., Brault A.C. MicroRNA reduction of neuronal West Nile virus replication attenuates and affords a protective immune response in mice. Vaccine. 2016;34:5366&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5683167</ArticleId><ArticleId IdType="pubmed">27637937</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.L., Lee Y.P., Wang Y.F., Lei H.Y., Liu C.C., Wang S.M., Su I.J., Wang J.R., Yeh T.M., Chen S.H., Yu C.K. Type I interferons protect mice against enterovirus 71 infection. J.&#xa0;Gen. Virol. 2005;86:3263&#x2013;3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.K., Chen C.C., Chen C.L., Wang J.R., Liu C.C., Yan J.J., Su I.J. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J.&#xa0;Biomed. Sci. 2000;7:523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Makeyev E.V., Zhang J., Carrasco M.A., Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol. Cell. 2007;27:435&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139456</ArticleId><ArticleId IdType="pubmed">17679093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeom K.H., Mitchell S., Linares A.J., Zheng S., Lin C.H., Wang X.J., Hoffmann A., Black D.L. Polypyrimidine tract-binding protein blocks miRNA-124 biogenesis to enforce its neuronal-specific expression in the mouse. Proc. Natl. Acad. Sci. USA. 2018;115:E11061&#x2013;E11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6255174</ArticleId><ArticleId IdType="pubmed">30401736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollmann G., Rogulin V., Simon I., Rose J.K., van den Pol A.N. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J.&#xa0;Virol. 2010;84:1563&#x2013;1573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812324</ArticleId><ArticleId IdType="pubmed">19906910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhawar S.R., Thandoni A., Bommareddy P.K., Hassan S., Kohlhapp F.J., Goyal S., Schenkel J.M., Silk A.W., Zloza A. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. Front. Oncol. 2017;7:202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600978</ArticleId><ArticleId IdType="pubmed">28955655</ArticleId></ArticleIdList></Reference><Reference><Citation>Polisetty R.V., Gautam P., Sharma R., Harsha H.C., Nair S.C., Gupta M.K., Uppin M.S., Challa S., Puligopu A.K., Ankathi P. LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol. Cell. Proteomics. 2012;11 M111.013565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433906</ArticleId><ArticleId IdType="pubmed">22219345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med. 2009;15:794&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Lee H., Hafenstein S., Kataoka C., Wakita T., Bergelson J.M., Shimizu H. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 2013;9:e1003511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.C., Shyu H.W., Chen S.H., Lei H.Y., Yu C.K., Yeh T.M. Enterovirus 71 infection induces Fas ligand expression and apoptosis of Jurkat cells. J.&#xa0;Med. Virol. 2006;78:780&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">16628611</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 2008;14:2900&#x2013;2908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430468</ArticleId><ArticleId IdType="pubmed">18483356</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L.W., Nishikawa T., Kaneda Y. An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis. Mol. Ther. 2016;24:135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754554</ArticleId><ArticleId IdType="pubmed">26548591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly K.R., Espitia C.M., Mahalingam D., Oyajobi B.O., Coffey M., Giles F.J., Carew J.S., Nawrocki S.T. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012;31:3023&#x2013;3038.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002308</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J.Z., Ziffra J., Stennett L., Bodner B., Bonish B.K., Chaturvedi V., Bennett F., Pollock P.M., Trent J.M., Hendrix M.J. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282&#x2013;6293.</Citation><ArticleIdList><ArticleId IdType="pubmed">16024630</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794896</ArticleId><ArticleId IdType="pubmed">19167326</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu. Rev. Pathol. 2014;9:287&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4009396</ArticleId><ArticleId IdType="pubmed">24079833</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 2009;10:578&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">19609263</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao X., Liang J., Huang C., Li K., Xing F., Zhu W., Lin Z., Xu W., Wu G., Zhang J. DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat. Commun. 2018;9:4342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6194050</ArticleId><ArticleId IdType="pubmed">30337542</ArticleId></ArticleIdList></Reference><Reference><Citation>Selman M., Rousso C., Bergeron A., Son H.H., Krishnan R., El-Sayes N.A., Varette O., Chen A., Le Boeuf F., Tzelepis F. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds. Mol. Ther. 2018;26:56&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5763159</ArticleId><ArticleId IdType="pubmed">29175158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos de Matos A., Franco L.S., McFadden G. Oncolytic Viruses and the Immune System: The Dynamic Duo. Mol. Ther. Methods Clin. Dev. 2020;17:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7015832</ArticleId><ArticleId IdType="pubmed">32071927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricca J.M., Oseledchyk A., Walther T., Liu C., Mangarin L., Merghoub T., Wolchok J.D., Zamarin D. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Mol. Ther. 2018;26:1008&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079372</ArticleId><ArticleId IdType="pubmed">29478729</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin N.T., Bell J.C. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Mol. Ther. 2018;26:1414&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986726</ArticleId><ArticleId IdType="pubmed">29703699</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo M.H., Hannemann H., Kulkarni A.S., Schwartz P.H., O&#x2019;Dowd J.M., Fortunato E.A. Human cytomegalovirus infection causes premature and abnormal differentiation of human neural progenitor cells. J.&#xa0;Virol. 2010;84:3528&#x2013;3541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838134</ArticleId><ArticleId IdType="pubmed">20071566</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Shimizu H., Nagata N., Ami Y., Suzaki Y., Sata T., Iwasaki T., Miyamura T. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J.&#xa0;Gen. Virol. 2005;86:1391&#x2013;1401.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831951</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrissy A.S., Morin R.D., Delaney A., Zeng T., McDonald H., Jones S., Zhao Y., Hirst M., Marra M.A. Next-generation tag sequencing for cancer gene expression profiling. Genome Res. 2009;19:1825&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765282</ArticleId><ArticleId IdType="pubmed">19541910</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann. Statist. 2001;29:1165&#x2013;1188.</Citation></Reference><Reference><Citation>Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., The Gene Ontology Consortium Gene ontology: tool for the unification of biology. Nat. Genet. 2000;25:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazanave S.C., Mott J.L., Elmi N.A., Bronk S.F., Werneburg N.W., Akazawa Y., Kahraman A., Garrison S.P., Zambetti G.P., Charlton M.R., Gores G.J. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J.&#xa0;Biol. Chem. 2009;284:26591&#x2013;26602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785347</ArticleId><ArticleId IdType="pubmed">19638343</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushima-Miyagi T., Hatano K., Nomura M., Li-Wen L., Nishikawa T., Saga K., Shimbo T., Kaneda Y. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin. Cancer Res. 2012;18:6271&#x2013;6283.</Citation><ArticleIdList><ArticleId IdType="pubmed">23014529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zheng Z., Liu X., Shu B., Mao P., Bai B., Hu Q., Luo M., Ma X., Cui Z., Wang H. Tick-borne encephalitis virus induces chemokine RANTES expression via activation of IRF-3 pathway. J.&#xa0;Neuroinflammation. 2016;13:209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004318</ArticleId><ArticleId IdType="pubmed">27576490</ArticleId></ArticleIdList></Reference><Reference><Citation>He B., Lin G.Y., Durbin J.E., Durbin R.K., Lamb R.A. The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells. J.&#xa0;Virol. 2001;75:4068&#x2013;4079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114152</ArticleId><ArticleId IdType="pubmed">11287556</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollmann G., Tattersall P., van den Pol A.N. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J.&#xa0;Virol. 2005;79:6005&#x2013;6022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1091699</ArticleId><ArticleId IdType="pubmed">15857987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekar V., Dreyer J.L. microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol. Cell. Neurosci. 2009;42:350&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19703567</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena J.T., Sohn-Lee C., Rouhanifard S.H., Ludwig J., Hafner M., Mihailovic A., Lim C., Holoch D., Berninger P., Zavolan M., Tuschl T. miRNA in&#xa0;situ hybridization in formaldehyde and EDC-fixed tissues. Nat. Methods. 2009;6:139&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838186</ArticleId><ArticleId IdType="pubmed">19137005</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>